Program
Tenofovir
Also written as “Tenofovir disoproxil fumarate”, “Tenofovir DF” and “tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · HIV Infections · Hepatitis B · Acquired Immunodeficiency Syndrome · Hepatitis C, led by 12 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 291 open or running | phase 4since Mar 23, 2005 | Nov 2, 1999 | none ahead |
| GlaxoSmithKline | 90 open or running | phase 4since May 31, 2002 | May 31, 2002 | none ahead |
| Hoffmann-La Roche | 30 open or running | phase 3since Mar 16, 2010 | Aug 19, 2009 | none ahead |
| Laboratorio Elea Phoenix | 20 open or running | phase 4since Oct 10, 2017 | Oct 19, 2015 | none ahead |
| Novartis | 20 open or running | phase 4since Dec 7, 2006 | Dec 7, 2006 | none ahead |
| Samjin Pharmaceutical | 20 open or running | phase 4since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| Boryung Pharmaceutical | 10 open or running | phase 1since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Daewoong Pharmaceutical | 10 open or running | phase 4since Mar 27, 2018 | Mar 27, 2018 | none ahead |
| Dong-A ST | 10 open or running | phase 1since Sep 22, 2015 | Sep 22, 2015 | none ahead |
| new-discovery-llc | 10 open or running | phase 4since Mar 18, 2018 | Mar 18, 2018 | none ahead |
| Viatris | 10 open or running | phase 4since Apr 25, 2022 | Apr 25, 2022 | none ahead |
| yung-shin-pharm-ind-co-ltd | 10 open or running | phase 4since Dec 15, 2020 | Dec 15, 2020 | none ahead |
Also a collaborator on its studies: c-r-research-inc, almedis and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 38 studies since Nov 2, 1999.
- Aug 21, 2012Phase 1 study in Hepatitis B, ChronicGilead Sciences · NCT01671787 · 51 enrolled · United States, Australia, Canada and more
- Jul 17, 2014Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT02195518 · 213 enrolled · China
- Aug 21, 2014Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT02224456 · 197 enrolled · China
- Jun 17, 2015Phase 4 study in Hepatitis BGilead Sciences · NCT02479880 · 30 enrolled · Belgium, France, Greece and more
- Sep 22, 2015Dong-A ST's first study: phase 1 study in Hepatitis BNew to Dong-A STDong-A ST · NCT02557594 · 36 enrolled · Korea, Republic of
- Oct 19, 2015Laboratorio Elea Phoenix's first study: phase 1 study in Acquired Immunodeficiency SyndromeNew to Laboratorio Elea PhoenixLaboratorio Elea Phoenix · NCT02583464 · 24 enrolled · Argentina
- Sep 29, 2016Boryung Pharmaceutical's first study: phase 1 study in HepatitisNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT02920931 · 50 enrolled · Korea, Republic of
- Aug 21, 2017Phase 4 study in Hepatitis B, ChronicGlaxoSmithKline · NCT03258710 · 75 enrolled · Japan
- Oct 10, 2017Phase 4 study in HealthyLaboratorio Elea Phoenix · NCT03309566 · 24 enrolled · Argentina
- Mar 18, 2018new-discovery-llc's first study: phase 4 study in Hepatitis BNew to new-discovery-llcnew-discovery-llc · NCT03476083 · 280 enrolled · China
- Mar 27, 2018Daewoong Pharmaceutical's first study: phase 4 study in Hepatitis B, ChronicNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT03485534 · 189 enrolled · Korea, Republic of
- Dec 15, 2020yung-shin-pharm-ind-co-ltd's first study: phase 4 study in Pharmacokinetic of Tenofovir in Healthy SubjectsNew to yung-shin-pharm-ind-co-ltdyung-shin-pharm-ind-co-ltd · NCT04671563 · 28 enrolled · Taiwan
- Feb 25, 2022Samjin Pharmaceutical's first studies: 2 phase 4 studies in Hepatitis B, ChronicNew to Samjin PharmaceuticalSamjin Pharmaceutical · NCT05286346, NCT05282407
- Apr 25, 2022Viatris's first study: phase 4 study in Hepatitis B, ChronicNew to ViatrisViatris · NCT05355467 · 40 enrolled · Taiwan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05355467Hepatitis B, Chronic · Taiwan | 4 | Completed | Viatris | Jul 13, 2021 | 40 |
| NCT05286346Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Samjin Pharmaceutical | Aug 10, 2020 | 113 |
| NCT05282407Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Samjin Pharmaceutical | Apr 17, 2019 | 118 |
| NCT04671563Pharmacokinetic of Tenofovir in Healthy Subjects · Taiwan | 4 | Completed | yung-shin-pharm-ind-co-ltd | May 9, 2020 | 28 |
| NCT03485534Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Daewoong Pharmaceutical | Nov 4, 2019 | 189 |
| NCT03476083Hepatitis B · China | 4 | UNKNOWN | new-discovery-llc | May 2021 | 280 |
| NCT03309566Healthy · Argentina | 4 | Completed | Laboratorio Elea Phoenix | Feb 28, 2017 | 24 |
| NCT03258710Hepatitis B, Chronic · Japan | 4 | Completed | GlaxoSmithKline | Dec 28, 2018 | 75 |
| NCT02920931Hepatitis · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Apr 2016 | 50 |
| NCT02583464Acquired Immunodeficiency Syndrome · Argentina | 1 | Completed | Laboratorio Elea Phoenix | Oct 2014 | 24 |
| NCT02557594Hepatitis B · Korea, Republic of | 1 | Completed | Dong-A ST | Nov 17, 2015 | 36 |
| NCT02479880Hepatitis B · Belgium, France, Greece and more | 4 | Terminated | Gilead Sciences | Feb 28, 2018 | 30 |
| NCT02224456Hepatitis B, Chronic · China | 4 | Completed | GlaxoSmithKline | Dec 4, 2020 | 197 |
| NCT02195518Hepatitis B, Chronic · China | 4 | Completed | GlaxoSmithKline | Aug 14, 2018 | 213 |
| NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more | 1 | Completed | Gilead Sciences | Apr 2013 | 51 |
| NCT01651403Hepatitis B, Chronic · United States, India, Romania and more | 3 | Active, not recruiting | Gilead Sciences | Aug 7, 2017 | 90 |
| NCT01592305Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Jun 2012 | 40 |
| NCT01480284Hepatitis B, Chronic · Japan | 3 | Completed | GlaxoSmithKline | Jan 2013 | 166 |
| NCT01480622Hepatitis B, Chronic · China | 1 | Completed | GlaxoSmithKline | Dec 30, 2011 | 14 |
| NCT01475851Hepatitis B, Chronic · Japan | 3 | Completed | GlaxoSmithKline | Jun 2013 | 34 |
| NCT01300234Hepatitis B · China | 3 | Completed | GlaxoSmithKline | Oct 17, 2012 | 512 |
| NCT01277601Hepatitis B, Chronic · United States, Australia, Canada and more | 4 | Completed | Gilead Sciences | Aug 2014 | 751 |
| NCT01334567Hepatitis B · Taiwan | 2 | Completed | Gilead Sciences | Dec 2013 | 30 |
| NCT01088659Hepatitis D, Chronic · Turkey | 3 | Completed | Hoffmann-La Roche | Dec 29, 2017 | 50 |
| NCT00962871Hepatitis B, Chronic · United States, New Zealand, Singapore and more | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 30 |
| NCT00737568Hepatitis B · United States, Austria, Bulgaria and more | 3 | Completed | Gilead Sciences | Nov 2011 | 280 |
| NCT00736190Hepatitis B, Chronic · United States | 4 | Completed | Gilead Sciences | Jul 2010 | 90 |
| NCT00734162Hepatitis B · United States, Bulgaria, France and more | 3 | Completed | Gilead Sciences | Mar 2011 | 106 |
| NCT00648817HIV Infections · United Kingdom | 4 | Completed | Gilead Sciences | Nov 2007 | 8 |
| NCT00647946Lipodystrophy · United Kingdom | 2 | Completed | Gilead Sciences | Oct 2004 | 100 |
| NCT00643968HIV Infections · France | 4 | Completed | Gilead Sciences | Jun 2005 | 140 |
| NCT00651209Hepatitis B, Chronic · Argentina, Brazil, Germany and more | 4 | Completed | Novartis | Dec 2011 | 105 |
| NCT00615745HIV Infections · United Kingdom | 4 | Completed | Gilead Sciences | Nov 2010 | 115 |
| NCT00528957HIV Infections · United States, Panama, United Kingdom | 3 | Completed | Gilead Sciences | Apr 6, 2009 | 97 |
| NCT00409019Hepatitis B, Chronic | 4 | Withdrawn | Novartis | Mar 2011 | 0 |
| NCT00365612HIV Infections · United States, Puerto Rico | 4 | Completed | Gilead Sciences | Oct 2007 | 300 |
| NCT00352053HIV Infections · Brazil, Panama | 3 | Completed | Gilead Sciences | Sep 2008 | 87 |
| NCT00324688HIV Infections · Germany | 4 | Completed | Gilead Sciences | 60 | |
| NCT00307489Hepatitis B, Chronic · United States, France, Germany and more | 2 | Completed | Gilead Sciences | Jan 2008 | 106 |
| NCT00298363Hepatitis B, Chronic · United States, Canada, France and more | 2 | Completed | Gilead Sciences | Apr 2011 | 112 |
| NCT00158821HIV Infections | 3 | Completed | Gilead Sciences | Dec 2001 | 180 |
| NCT00112047HIV Infections · United States | 3 | Completed | Gilead Sciences | Feb 2005 | 517 |
| NCT00106379HIV Infections · United States | 4 | Completed | Gilead Sciences | 52 | |
| NCT00053638HIV Infections · United States | 3 | Completed | GlaxoSmithKline | Oct 2004 | 345 |
| NCT00038506HIV Infections · United States | 4 | Completed | GlaxoSmithKline | Aug 2004 | 100 |
| NCT00016588HIV Infections · United States | – | Completed | Gilead Sciences | ||
| NCT00011089HIV Infections · United States | – | UNKNOWN | Gilead Sciences | ||
| NCT00007436HIV Infections · United States | 3 | UNKNOWN | Gilead Sciences | ||
| NCT00002453HIV Infections · United States | – | Completed | Gilead Sciences | 300 | |
| NCT00002450HIV Infections · United States, Puerto Rico | 3 | Completed | Gilead Sciences | 600 | |
| NCT00002415HIV Infections · United States | 2 | Completed | Gilead Sciences | 175 | |
| NCT00002396HIV Infections · United States | 1 | UNKNOWN | Gilead Sciences | 60 | |
| NCT00002180HIV Infections · United States | 1 | Completed | Gilead Sciences |
How it is read
Names in the registry
- “Tenofovir disoproxil fumarate”, 13 entries
- “Tenofovir”, 7 entries
- “Tenofovir DF”, 6 entries
- “tenofovir”, 5 entries
- “TDF”, 4 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 29 studies
- HIV Infections, 23 studies
- Hepatitis B, 6 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Hepatitis C, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.